UPDATED: Hat tip to FTD — from Bloomberg, reporting today!
…Kocher also questioned Shkreli’s dual roles, handling what was left of his hedge fund clients’ money while running Retrophin.
“I am also aware that you manage both companies, which seems to be a conflict of interest if our hedge fund doesn’t benefit from Retrophin,” he wrote.
Shkreli didn’t immediately reply to Kocher’s questions and at one point rebuffed him, replying he was “busy running the company,” referring to Retrophin.
Asked by a prosecutor for his reaction to Shkreli’s delays, Kocher told jurors: “I don’t think it mattered to him. It was more about what he could get away with….”
[End, updated portion — with no word on what the morning’s cross examination of Mr. Su covered.]
The witnesses for the prosecution will continue today — with cross examination of Mr. Jackson Su by the defense up first (I believe).
Feel free to add your thoughts and links.
If I get time, after a FINRA arbitration — I may add some more filled in thoughts, on the discussion in comments to prior posts — about how FDA seems poised to regulate Turing’s (and thus Shkreli’s) “business” model (to the extent price gouging can ever be called a business model) out of existence.
We shall see. Onward, now one and all — of good will… keep it flowing in good karma, even as we get drenched here in the city of big shoulders.